Bausch Health Cos Inc. (NYSE:BHC - Free Report) - Research analysts at Zacks Research upped their Q4 2026 earnings per share estimates for Bausch Health Cos in a research report issued to clients and investors on Wednesday, November 18th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $1.17 for the quarter, up from their previous forecast of $1.16. Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for Bausch Health Cos' current full-year earnings is $4.53 per share. Zacks Research also issued estimates for Bausch Health Cos' Q1 2027 earnings at $0.85 EPS, Q2 2027 earnings at $0.95 EPS, Q3 2027 earnings at $1.05 EPS, Q4 2027 earnings at $1.05 EPS, FY2027 earnings at $3.89 EPS, Q1 2028 earnings at $0.68 EPS and Q2 2028 earnings at $0.89 EPS.
Bausch Health Cos (NYSE:BHC - Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The company reported $1.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.25 by $0.52. The company had revenue of $2.90 billion during the quarter, compared to the consensus estimate of $2.72 billion. Bausch Health Cos had a negative return on equity of 401.73% and a negative net margin of 7.57%.
BHC has been the subject of a number of other reports. Jefferies Financial Group increased their price objective on shares of Bausch Health Cos from $6.50 to $8.00 and gave the stock a "hold" rating in a research note on Thursday, October 29th. Wall Street Zen upgraded shares of Bausch Health Cos from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 1st. Royal Bank Of Canada upped their target price on shares of Bausch Health Cos from $9.00 to $10.00 and gave the stock a "sector perform" rating in a report on Thursday, October 29th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Bausch Health Cos in a report on Thursday, October 29th. Finally, Barclays increased their price target on Bausch Health Cos from $7.00 to $9.00 and gave the stock an "equal weight" rating in a research note on Wednesday, November 11th. Six equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Reduce" and a consensus target price of $8.75.
View Our Latest Stock Report on Bausch Health Cos
Bausch Health Cos Price Performance
Shares of NYSE:BHC opened at $8.73 on Thursday. Bausch Health Cos has a 1-year low of $4.33 and a 1-year high of $9.04. The company has a market capitalization of $3.27 billion, a P/E ratio of -3.81 and a beta of 0.30. The firm's 50 day simple moving average is $6.70 and its two-hundred day simple moving average is $5.84.
Institutional Investors Weigh In On Bausch Health Cos
Institutional investors and hedge funds have recently modified their holdings of the stock. Paulson & CO. Inc. purchased a new position in Bausch Health Cos during the second quarter valued at $361,151,000. The Manufacturers Life Insurance Company bought a new stake in Bausch Health Cos in the 2nd quarter valued at $1,167,000. Dimensional Fund Advisors LP increased its holdings in Bausch Health Cos by 10.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,604,818 shares of the company's stock valued at $19,456,000 after acquiring an additional 350,823 shares during the last quarter. MFN Partners Management LP bought a new stake in Bausch Health Cos in the 2nd quarter valued at $29,580,000. Finally, Bank of America Corp DE purchased a new stake in Bausch Health Cos in the 2nd quarter worth $2,816,000. Institutional investors own 78.65% of the company's stock.
Bausch Health Cos Company Profile
(
Get Free Report)
Bausch Health Companies Inc. is a global specialty pharmaceutical and medical products company headquartered in Laval, Quebec. It develops, manufactures and markets prescription medicines, over-the-counter products and medical devices, with businesses spanning eye health, gastroenterology, dermatology, neurology and aesthetics. Its portfolio includes Salix products for gastrointestinal conditions, Ortho Dermatologics treatments for skin conditions and Solta Medical aesthetic devices. Bausch Health also retains a controlling ownership interest in Bausch + Lomb, a publicly traded eye-health company whose products include contact lenses, lens care products, pharmaceuticals and surgical devices.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bausch Health Cos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Cos wasn't on the list.
While Bausch Health Cos currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.